Global Acute Myeloid Leukemia Therapeutics Market - 2025-2033

October 2025 | 68 pages | ID: GF23A57F125CEN
DataM Intelligence

Abstracts

Global Acute Myeloid Leukemia Therapeutics Market reached US$ 2.89 Billion in 2023 and is expected to reach US$ 7.25 Billion by 2033, growing with a CAGR of 9.70% during the forecast period 2026-2033.

The Global Acute Myeloid Leukemia Therapeutics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Global Acute Myeloid Leukemia Therapeutics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug Class

• Targeted Therapy *
• FLT3 Inhibitors
• IDH Inhibitors
• Mylotarg
• BCL-2 Inhibitor
• Hedgehog Pathway Inhibitor
• Menin Inhibitor
• Chemotherapy
• Antimetabolites
• Cytarabine
• 5-Aza-cytidine
• Decitabine
• Fludarabine
• Others
• Alkylating Agents
• Cyclophosphamide
• Melphalan
• Busulfan
• Treosulfan
• Anthracycline Drugs
• Daunorubicin
• Idarubicin
• Doxorubicin
• Mitoxantrone
• Others
• Immunotherapy
• Bispecific Antibodies
• Antibody-drug Conjugates
• Immune Checkpoint Inhibitors
• Chimeric Antigen Receptor (CAR) T-cell Therapy
• Others

By Disease Type

• Myeloblastic Leukemia*
• Myelomonocytic Leukemia
• Promyelocytic Leukemia
• Monocytic Leukemia
• Others

By Route of Administration

• Parenteral*
• Oral

By Distribution Channel

• Hospital Pharmacy*
• Retail Pharmacy
• Online Pharmacy

Regional Analysis for Global Acute Myeloid Leukemia Therapeutics Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Global Acute Myeloid Leukemia Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Class
2.4. Snippet by Disease Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Growing Incidence of Acute Myeloid Leukemia
    3.1.1.2. Advancements in Targeted and Personalized Therapies
  3.1.2. Restraints
    3.1.2.1. Disease Heterogeneity
    3.1.2.2. High Treatment Costs
  3.1.3. Opportunity
    3.1.3.1. Advancements in CAR-T Cell Therapy
    3.1.3.2. Development of Combination Therapies

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established Leaders with the Largest Marketing Brand
  4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
  4.4.1. Bargaining Power of Suppliers
  4.4.2. Bargaining Power of Buyers
  4.4.3. Threat of Substitutes
  4.4.4. Threat of New Entrants
  4.4.5. Competitive Rivalry
4.5. Patent Analysis
  4.5.1. Patent Expiry and Exclusivity
  4.5.2. Key Patent Holders
  4.5.3. Patent Litigations
  4.5.4. Licensing Opportunities
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
  4.8.1. Price Benchmarking vs Competitors
  4.8.2. Reimbursement Landscape
  4.8.3. Pricing Trends by Region or Segment
  4.8.4. Value-based Pricing Opportunities

5. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  5.1.2. Market Attractiveness Index, By Drug Class
5.2. Targeted Therapy *
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  5.2.3. FLT3 Inhibitors
  5.2.4. IDH Inhibitors
  5.2.5. Mylotarg
  5.2.6. BCL-2 Inhibitor
  5.2.7. Hedgehog Pathway Inhibitor
  5.2.8. Menin Inhibitor
5.3. Chemotherapy
  5.3.1. Antimetabolites
    5.3.1.1. Cytarabine
    5.3.1.2. 5-Aza-cytidine
    5.3.1.3. Decitabine
    5.3.1.4. Fludarabine
    5.3.1.5. Others
  5.3.2. Alkylating Agents
    5.3.2.1. Cyclophosphamide
    5.3.2.2. Melphalan
    5.3.2.3. Busulfan
    5.3.2.4. Treosulfan
    5.3.2.5. Others
  5.3.3. Anthracycline Drugs
    5.3.3.1. Daunorubicin
    5.3.3.2. Idarubicin
    5.3.3.3. Doxorubicin
    5.3.3.4. Mitoxantrone
    5.3.3.5. Others
  5.3.4. Others
5.4. Immunotherapy
  5.4.1. Bispecific Antibodies
  5.4.2. Antibody-drug Conjugates
  5.4.3. Immune Checkpoint Inhibitors
  5.4.4. Chimeric Antigen Receptor (CAR) T-cell Therapy
5.5. Others

6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DISEASE TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  6.1.2. Market Attractiveness Index, By Disease Type
6.2. Myeloblastic Leukemia*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Myelomonocytic Leukemia
6.4. Promyelocytic Leukemia
6.5. Monocytic Leukemia
6.6. Others

7. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Parenteral*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral

8. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy

9. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10. INTRODUCTION

10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.1. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.7.1. U.S.
    10.2.7.2. Canada
    10.2.7.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.7.1. Germany
    10.3.7.2. UK
    10.3.7.3. France
    10.3.7.4. Spain
    10.3.7.5. Italy
    10.3.7.6. Rest of Europe
10.4. Asia-Pacific
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.7.1. China
    10.4.7.2. India
    10.4.7.3. Japan
    10.4.7.4. South Korea
    10.4.7.5. Rest of Asia-Pacific
10.5. South America
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.7.1. Brazil
    10.5.7.2. Argentina
    10.5.7.3. Rest of South America
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

12.1. Market Share Analysis and Positioning Matrix
12.2. Strategic Partnerships, Mergers & Acquisitions
12.3. Key Developments in Product Portfolios and Innovations
12.4. Company Benchmarking

13. COMPANY PROFILES

13.1. Genentech, Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
    13.1.2.1. Product Description
    13.1.2.2. Product Key Performance Indicators (KPIs)

14. FINANCIAL OVERVIEW

14.1. Company Revenue
  14.1.1. Geographical Revenue Shares
    14.1.1.1. Revenue Forecasts
  14.1.2. Key Developments
    14.1.2.1. Mergers & Acquisitions
    14.1.2.2. Key Product Development Activities
    14.1.2.3. Regulatory Approvals, etc.
  14.1.3. SWOT Analysis
14.2. Servier Pharmaceuticals LLC.
14.3. Bristol-Myers Squibb Company.
14.4. Rigel Pharmaceuticals, Inc.
14.5. Novartis AG
14.6. Astellas Pharma Inc.
14.7. Daiichi Sankyo, Inc.
14.8. Jazz Pharmaceuticals plc
14.9. Pfizer Inc.
14.10. Teva Pharmaceutical Industries Ltd. (LIST NOT EXHAUSTIVE)

15. ASSUMPTIONS AND RESEARCH METHODOLOGY

15.1. Data Collection Methods
15.2. Data Triangulation
15.3. Forecasting Techniques
15.4. Data Verification and Validation

16. APPENDIX

16.1. About Us and Services
16.2. Contact Us